UNITED STATES INTERNATIONAL TRADE COMMISSION
Washington, D.C.

In the Matter of **CERTAIN BLOOD SEPARATION AND CELL PREPARATION DEVICES**	**Investigation No. 337-TA-1147**

NOTICE OF COMMISSION DETERMINATION NOT TO REVIEW AN INITIAL DETERMINATION TERMINATING THE INVESTIGATION WITH RESPECT TO CERTAIN ASSERTED CLAIMS

AGENCY: U.S. International Trade Commission.

ACTION: Notice.

SUMMARY: Notice is hereby given that the U.S. International Trade Commission has determined not to review an initial determination ("ID") (Order No. 7) of the presiding administrative law judge ("ALJ"), granting complainant's unopposed motion for partial termination of the investigation with respect to certain asserted claims.

FOR FURTHER INFORMATION CONTACT: Cathy Chen, Esq., Office of the General Counsel, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436, telephone (202) 205-2392. Copies of non-confidential documents filed in connection with this investigation are or will be available for inspection during official business hours (8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436, telephone (202) 205-2000. General information concerning the Commission may also be obtained by accessing its Internet server at *https://www.usitc.gov*. The public record for this investigation may be viewed on the Commission's electronic docket (EDIS) at *https://edis.usitc.gov*. Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission's TDD terminal on (202) 205-1810.

SUPPLEMENTARY INFORMATION: The Commission instituted this investigation on March 12, 2019, based on a complaint filed on behalf of RegenLab USA LLC ("RegenLab") of New York, New York. 84 FR 8891 (Mar. 12, 2019). The complaint, as amended, alleges violations of section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, in the importation into the United States, the sale for importation, or the sale within the United States after importation of certain blood separation and cell preparation devices by reason of infringement of one or more claims of U.S. Patent No. 10,064,894 ("the '894 patent"). *Id.* The complaint further alleges that a domestic industry exists. *Id.* The Commission's notice of investigation named as respondents Estar Technologies, Ltd. of Holon, Israel; and Eclipse

MedCorp, LLC of The Colony, Texas. *Id.* at 8892. The Office of Unfair Import Investigations is also participating in the investigation. *Id.*

On June 3, 2019, RegenLab filed an unopposed motion to withdraw its allegations of infringement as to claims 2-5 and 10-17 of the '894 patent. On June 5, 2019, the ALJ issued the subject ID granting the motion. The ALJ found that the requirements of Commission Rule 210.21(a)(1) have been met and that no extraordinary circumstances prevent granting the motion. *See* Order No. 7 at 1-2 (Jun. 5, 2019). No petitions for review were filed.

The authority for the Commission's determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in part 210 of the Commission's Rules of Practice and Procedure (19 CFR 210).

By order of the Commission.

Lisa R. Barton
Secretary to the Commission

Issued: July 1, 2019